IPO Journey
Mobia Medical, Inc.
IPO Date: May 8, 2026 · 4 filings tracked
Final Offer Terms
Ticker
MOBI
Exchange
Nasdaq Global Select Market
Offer Price
$15.00
Shares Offered
10,000,000
Estimated Proceeds
$150.0M
Underwriters
Led by BofA Securities, J.P. Morgan
Goldman Sachs & Co. LLCBTIGWolfe | Nomura Alliance
Filing Timeline
1
S-1
April 17, 2026
- FDA-approved Vivistim System offers a breakthrough 'brain trainer' for chronic stroke recovery.
- Rapid revenue growth, more than doubling from $15.6 million in 2024 to $32 million in 2025.
2
S-1/A
April 27, 2026
- Exclusive FDA-approved Vivistim System for chronic stroke recovery
- Rapid revenue growth, more than doubling from 2024 to 2025
Changes from previous filing
- ▸ Exchange: Nasdaq Global Select Market
3
S-1/A
May 4, 2026
- FDA-approved Vivistim System offers a breakthrough in stroke rehabilitation.
- Rapid revenue growth, doubling from $15.6M in 2024 to $32M in 2025.
Changes from previous filing
- ▸ Expected offer range: $14.0 – $16.0 per share
- ▸ Shares offered: 10,000,000
- ▸ Estimated proceeds: $140M
424B4
Final Pricing
May 8, 2026
- Pioneering a new medical category for chronic stroke recovery
- First FDA-approved device for arm and hand movement restoration
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $15.0 per share
- ▸ Estimated proceeds: $150M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.